Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 3/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633896 | 0.90 | KDM1A (0.46) | KDM1ACNR1CNR2RORCHDAC2 | |
| SCHEMBL4634342 | 0.89 | HDAC2 (0.46) | KDM1ACNR1CNR2RORCHDAC2 | |
| SCHEMBL5674689 | 0.87 | MEN1 (0.45) | KDM1ACNR1CNR2RORCHDAC2 | |
| SCHEMBL3353600 | 0.85 | RORC (0.46) | KDM1ACNR1CNR2RORCHDAC2 | |
| SCHEMBL5672759 | 0.85 | CNR1 (0.45) | KDM1ACNR1CNR2RORCHDAC2 | |
| SCHEMBL4635507 | 0.85 | KDM1A (0.43) | KDM1ACNR1CNR2RORCHDAC2 | |
| SCHEMBL5672765 | 0.85 | KDM1A (0.48) | KDM1ACNR1CNR2RORCHDAC2 | |
| SCHEMBL4634695 | 0.85 | HDAC2 (0.48) | KDM1ACNR1CNR2RORCHDAC2 | |
| SCHEMBL14357682 | 0.85 | KDM1A (0.48) | KDM1ACNR1CNR2RORCHDAC2 | |
| SCHEMBL16986971 | 0.85 | GPR119 (0.52) | HDAC1KMT2AMEN1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2021-10-26 | — | — | US | disclosed |
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-01-28 | — | — | US | disclosed |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-01-28 | — | — | US | disclosed |
| US-20150225394-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225375-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225375-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885CNR1 658/4885CNR2 766/4885 |
| US-20150225375-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885CNR1 658/4885CNR2 766/4885 |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885CNR1 658/4885CNR2 766/4885 |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR4, CCR5 | KDM1A 1463/4885CNR1 27/4885CNR2 53/4885 |
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | KDM1A 2/4885CNR1 658/4885CNR2 766/4885 |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | KDM1A 2/4885CNR1 658/4885CNR2 766/4885 |
| US-20150225394-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885CNR1 658/4885CNR2 766/4885 |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885CNR1 658/4885CNR2 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.